CO7350619A2 - Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina - Google Patents
Compuestos heteroaromáticos y su uso como ligandos d1 de dopaminaInfo
- Publication number
- CO7350619A2 CO7350619A2 CO15105499A CO15105499A CO7350619A2 CO 7350619 A2 CO7350619 A2 CO 7350619A2 CO 15105499 A CO15105499 A CO 15105499A CO 15105499 A CO15105499 A CO 15105499A CO 7350619 A2 CO7350619 A2 CO 7350619A2
- Authority
- CO
- Colombia
- Prior art keywords
- disorder
- post
- compounds
- schizophrenia
- chronic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Abstract
La presente invención proporciona, en parte, compuestos de la Formula I: y sales farmaceuticamente aceptables de los mismos y N-óxidos de los anteriores; procesos para la preparación de; y composiciones que contienen dichos compuestos, sales o N-óxidos, y sus usos para el tratamiento de padecimientos mediados por D1 (o asociados con D1) que incluyen por ejemplo, esquizofrenia (por ejemplo sus síntomas cognitivos y negativos), deterioro cognitivo asociado con esquizofrenia, AD, PD, o terapia de farmacoterapia), ADHD, impulsividad, ludopatía, comer en exceso, trstorno del espectro autista, MCI, deterioro cognitivo relacionado con la edad, demencia, RLS, enfermedad de Parkinson, corea de Hungtinton, ansiedad, depresión, MDD, TRD, trastorno bipolar, apatía crónica anhedonia, fatifga crónica, trstorno por estrés post-traumático, trastorno afectivo estacional, trastorno de ansiedad social, depresión post-parto, síndrome de la serotonina, abuso de sustancias y farmacodependencia, recaída en el abuso de fármacos, sindrome de Tourette, disquinesia tardía, somnolencia, somnolencia diurna excesiva, caquexia, falta de atención, disfunción sexual, migraña, SLE, hiperglucemia, ateroscleosis, didlipidemia, obesidad, diabetes, sepesis, necrosisi tubular post-isquémica, insuficiencia renal, hiponatremia, edema resistente, narcolepsia, hipertensión, insuficiencia cardíaca congestiva, hipotonía ocular post-operatoria, tratornos del sueño, y dolor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723995P | 2012-11-08 | 2012-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7350619A2 true CO7350619A2 (es) | 2015-08-10 |
Family
ID=49955424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO15105499A CO7350619A2 (es) | 2012-11-08 | 2015-05-08 | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8822494B2 (es) |
| EP (1) | EP2917216B1 (es) |
| JP (1) | JP5823657B1 (es) |
| KR (1) | KR101660664B1 (es) |
| CN (1) | CN104837839A (es) |
| AP (1) | AP3861A (es) |
| AR (1) | AR095359A1 (es) |
| AU (1) | AU2013343105B2 (es) |
| BR (1) | BR112015010412A2 (es) |
| CA (1) | CA2889572C (es) |
| CL (1) | CL2015001233A1 (es) |
| CO (1) | CO7350619A2 (es) |
| CR (1) | CR20150237A (es) |
| EA (1) | EA201500402A1 (es) |
| ES (1) | ES2652514T3 (es) |
| GE (1) | GEP201606598B (es) |
| HK (1) | HK1213256A1 (es) |
| IL (1) | IL238712A0 (es) |
| MA (1) | MA38069A1 (es) |
| MD (1) | MD20150037A2 (es) |
| MX (1) | MX2015005506A (es) |
| NI (1) | NI201500066A (es) |
| PE (1) | PE20150966A1 (es) |
| PH (1) | PH12015500883A1 (es) |
| SG (1) | SG11201502884TA (es) |
| TN (1) | TN2015000167A1 (es) |
| TW (1) | TWI577678B (es) |
| UA (1) | UA111687C2 (es) |
| UY (1) | UY35129A (es) |
| WO (1) | WO2014072882A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014072881A1 (en) | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| WO2014072882A1 (en) * | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Heteroaromatic compounds as dopamine d1 ligands |
| EP3013813B1 (en) * | 2013-06-27 | 2019-04-03 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
| CA2946471C (en) | 2014-04-25 | 2018-08-07 | Pfizer Inc. | Fused bicyclic heteroaromatic compounds and their use as dopamine d1 ligands |
| WO2015162518A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| BR112016023740A2 (pt) | 2014-04-25 | 2017-08-15 | Pfizer | compostos heteroaromáticos e seu uso como ligantes de dopamina d1 |
| JP6564394B2 (ja) | 2014-04-28 | 2019-08-21 | ファイザー・インク | 複素環式化合物およびそのドーパミンｄ１リガンドとしての使用 |
| WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| CN103992319B (zh) * | 2014-05-27 | 2015-09-16 | 天津市斯芬克司药物研发有限公司 | 一种吡啶羧酸类化合物的制备方法 |
| EP3644996B1 (en) * | 2017-06-28 | 2023-07-26 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
| CA3104811C (en) | 2017-06-30 | 2024-05-28 | Chase Therapeutics Corporation | Composition comprising pramipexole and nk1-antagonists for treating depression |
| PE20230838A1 (es) | 2020-06-22 | 2023-05-19 | Hoffmann La Roche | Derivados de sulfona |
| CN115340500A (zh) * | 2021-05-14 | 2022-11-15 | 广东东阳光药业有限公司 | 一种含硫化合物的制备方法 |
| CN118401513A (zh) * | 2022-01-29 | 2024-07-26 | 苏州科睿思制药有限公司 | 他伐帕敦的晶型及其制备方法和用途 |
| CN114751855B (zh) * | 2022-05-23 | 2024-05-07 | 上海皓鸿生物医药科技有限公司 | 一种2-溴-4-氨基-5-甲基吡啶的制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US6395733B1 (en) | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
| MXPA06000554A (es) | 2003-07-14 | 2006-07-03 | Arena Pharm Inc | Derivados arilo y heteroarilo fusionados como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con los mismos. |
| WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| CN101124228B (zh) | 2004-12-14 | 2011-06-15 | 阿斯利康(瑞典)有限公司 | 用作抗肿瘤药物的吡唑并嘧啶化合物 |
| WO2006077401A1 (en) * | 2005-01-19 | 2006-07-27 | Biolipox Ab | Pyrrolopyridines useful in the treatment of inflammation |
| US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
| WO2007103308A2 (en) | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| CA2689092C (en) | 2007-06-07 | 2013-01-15 | Amgen Inc. | Raf kinase modulators and methods of use |
| US7829567B2 (en) | 2007-10-31 | 2010-11-09 | Kaohsiung Medical University | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same |
| WO2009073777A1 (en) | 2007-12-06 | 2009-06-11 | Schering Corporation | Gamma secretase modulators |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| UY31984A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
| MX2011002263A (es) | 2008-09-10 | 2011-05-23 | Kalypsys Inc | Aminopirimidinas como inhibidores de receptores de histamina para el tratamiento de enfermedades. |
| ES2435918T3 (es) | 2008-09-26 | 2013-12-26 | National Health Research Institutes | Compuestos multicíclicos condensados como inhibidores de las proteína-cinasas |
| WO2010106333A1 (en) * | 2009-03-19 | 2010-09-23 | Medical Research Council Technology | Compounds |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| CA2765053C (en) | 2009-06-09 | 2015-08-18 | California Capital Equity, Llc | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
| EP2456443A1 (en) | 2009-07-21 | 2012-05-30 | Gilead Calistoga LLC | Treatment of liver disorders with pi3k inhibitors |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| WO2012003274A1 (en) | 2010-07-01 | 2012-01-05 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
| AU2011272850A1 (en) | 2010-07-02 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
| WO2014072882A1 (en) * | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Heteroaromatic compounds as dopamine d1 ligands |
| WO2014072881A1 (en) * | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
-
2013
- 2013-10-30 WO PCT/IB2013/059768 patent/WO2014072882A1/en active Application Filing
- 2013-10-30 MD MDA20150037A patent/MD20150037A2/ro not_active Application Discontinuation
- 2013-10-30 EP EP13820925.9A patent/EP2917216B1/en active Active
- 2013-10-30 UA UAA201504509A patent/UA111687C2/uk unknown
- 2013-10-30 AP AP2015008382A patent/AP3861A/en active
- 2013-10-30 GE GEAP201313820A patent/GEP201606598B/en unknown
- 2013-10-30 BR BR112015010412A patent/BR112015010412A2/pt not_active IP Right Cessation
- 2013-10-30 PE PE2015000612A patent/PE20150966A1/es not_active Application Discontinuation
- 2013-10-30 CN CN201380063892.3A patent/CN104837839A/zh active Pending
- 2013-10-30 CA CA2889572A patent/CA2889572C/en active Active
- 2013-10-30 JP JP2015540249A patent/JP5823657B1/ja active Active
- 2013-10-30 AU AU2013343105A patent/AU2013343105B2/en not_active Ceased
- 2013-10-30 KR KR1020157014721A patent/KR101660664B1/ko active IP Right Grant
- 2013-10-30 MX MX2015005506A patent/MX2015005506A/es unknown
- 2013-10-30 ES ES13820925.9T patent/ES2652514T3/es active Active
- 2013-10-30 EA EA201500402A patent/EA201500402A1/ru unknown
- 2013-10-30 SG SG11201502884TA patent/SG11201502884TA/en unknown
- 2013-11-05 US US14/072,563 patent/US8822494B2/en active Active
- 2013-11-07 AR ARP130104095A patent/AR095359A1/es unknown
- 2013-11-07 TW TW102140555A patent/TWI577678B/zh not_active IP Right Cessation
- 2013-11-08 UY UY0001035129A patent/UY35129A/es not_active Application Discontinuation
-
2014
- 2014-07-23 US US14/339,123 patent/US9133190B2/en active Active
-
2015
- 2015-04-21 PH PH12015500883A patent/PH12015500883A1/en unknown
- 2015-04-30 TN TNP2015000167A patent/TN2015000167A1/fr unknown
- 2015-05-05 MA MA38069A patent/MA38069A1/fr unknown
- 2015-05-07 IL IL238712A patent/IL238712A0/en unknown
- 2015-05-07 CL CL2015001233A patent/CL2015001233A1/es unknown
- 2015-05-07 NI NI201500066A patent/NI201500066A/es unknown
- 2015-05-08 CO CO15105499A patent/CO7350619A2/es unknown
- 2015-05-08 CR CR20150237A patent/CR20150237A/es unknown
- 2015-08-06 US US14/819,541 patent/US9527843B2/en active Active
-
2016
- 2016-02-02 HK HK16101174.8A patent/HK1213256A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7350619A2 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| CU20150180A7 (es) | Piridin-2 que contienen il-4-derivados sustituidos de 1-diazino fenilo útiles como ligandos de dopamina | |
| UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
| AR079542A1 (es) | Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars. | |
| GT201300179A (es) | Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos | |
| ECSP12012098A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
| ECSP13012900A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos | |
| CL2007003261A1 (es) | Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, tales como esquizofrenia, | |
| CL2011001094A1 (es) | Compuesto derivados de pirazin-2-iloxi, inhibidores de pde10; composición farmacéutica que comprende a los compuestos; y uso de los compuestos en la preparación de medicamentos para tratar enfermedades, tales como obesidad, diabetes no dependiente de insulina, esquizofernia, bipolaridad, trastorno obsesivo-compulsivo y similares. | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| UY31803A (es) | Compuesto cristalino | |
| ECSP10010231A (es) | Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. | |
| CL2013003485A1 (es) | Compuestos derivados de benzamida sustituida como moduladores de receptores asociados con las aminas traza (taar1); composición farmacéutica; procedimiento de preparación; y uso en el tratamiento de depresión, psicosis, enfermedad de parkinson, ansiedad, trastorno de hiperactividad (adhd) y diabetes. | |
| PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
| PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| ATE481972T1 (de) | Chinazolinon-derivate als vanilloid-antagonisten | |
| PH12019500119A1 (en) | Ethynyl derivatives | |
| EA201692404A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
| MX2015008034A (es) | Benzazepinas como ligandos de receptor de serotonina 5-ht2c y usos de las mismas. | |
| EA200802000A1 (ru) | Фармацевтически приемлемые соли и полиморфные формы | |
| EA201992076A1 (ru) | Ингибиторы бета-секретазы |